Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$275.42
-1.0%
$326.24
$261.59
$473.50
$7.85B0.87203,243 shs164,771 shs
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
N/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
$18.13
+0.4%
$17.93
$4.18
$18.31
$2.73B1.171.70 million shs116,525 shs
PureTech Health plc stock logo
PRTC
PureTech Health
$27.48
$26.55
$17.08
$34.00
$741.96M1.233,004 shs41 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-2.65%-4.38%-18.49%-12.14%-36.41%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%+1.87%
ERGO
Entia Biosciences
0.00%0.00%0.00%0.00%-50.00%
MorphoSys AG stock logo
MOR
MorphoSys
+0.06%+0.06%-0.55%+82.88%+252.54%
PureTech Health plc stock logo
PRTC
PureTech Health
+5.09%+2.02%-11.10%+8.87%+3.27%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.6066 of 5 stars
3.43.00.04.21.83.31.9
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
0.6595 of 5 stars
1.25.00.00.03.00.00.6
PureTech Health plc stock logo
PRTC
PureTech Health
0.3012 of 5 stars
0.03.00.00.03.10.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.80
Moderate Buy$468.0069.92% Upside
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/A
ERGO
Entia Biosciences
N/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
2.38
Hold$11.78-35.02% Downside
PureTech Health plc stock logo
PRTC
PureTech Health
N/AN/AN/AN/A

Current Analyst Ratings

Latest BIO, MOR, ERGO, BLU, and PRTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$400.00 ➝ $365.00
3/14/2024
MorphoSys AG stock logo
MOR
MorphoSys
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$17.00 ➝ $18.25
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$395.00 ➝ $420.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$484.00 ➝ $480.00
2/5/2024
MorphoSys AG stock logo
MOR
MorphoSys
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$17.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.67B2.94$11.69 per share23.57$306.51 per share0.90
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
$257.89M10.59N/AN/A$0.35 per share51.80
PureTech Health plc stock logo
PRTC
PureTech Health
$15.62M47.50N/AN/A$19.64 per share1.40

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$637.32M-$21.49N/A24.03N/A-23.86%3.90%2.77%5/7/2024 (Confirmed)
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
ERGO
Entia Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$1.56N/AN/AN/A-80.07%-694.31%-8.96%5/1/2024 (Estimated)
PureTech Health plc stock logo
PRTC
PureTech Health
-$50.35MN/A0.00N/AN/AN/AN/AN/A4/26/2024 (Estimated)

Latest BIO, MOR, ERGO, BLU, and PRTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.04N/A-$2.04N/AN/AN/A  
3/13/2024Q4 2023
MorphoSys AG stock logo
MOR
MorphoSys
-$0.92$0.33+$1.25$0.33$76.30 million$63.53 million
2/15/2024Q4 2023
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.93$3.10+$0.17-$5.94$685.00 million$681.18 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
PureTech Health plc stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.14
5.83
4.34
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
ERGO
Entia Biosciences
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
4.98
3.08
2.84
PureTech Health plc stock logo
PRTC
PureTech Health
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
ERGO
Entia Biosciences
N/A
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
PureTech Health plc stock logo
PRTC
PureTech Health
0.04%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.06%
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
ERGO
Entia Biosciences
28.30%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
PureTech Health plc stock logo
PRTC
PureTech Health
5.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
8,03028.52 million23.65 millionOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
524150.62 million150.55 millionNot Optionable
PureTech Health plc stock logo
PRTC
PureTech Health
11127.00 million25.56 millionNot Optionable

BIO, MOR, ERGO, BLU, and PRTC Headlines

SourceHeadline
PureTech Announces Annual Results for Year Ended December 31, 2023PureTech Announces Annual Results for Year Ended December 31, 2023
finance.yahoo.com - April 25 at 9:10 AM
PureTech Health (NASDAQ:PRTC) Shares Gap Down to $26.94PureTech Health (NASDAQ:PRTC) Shares Gap Down to $26.94
americanbankingnews.com - April 21 at 4:42 AM
PureTech Health: Notice of ResultsPureTech Health: Notice of Results
businesswire.com - April 18 at 2:00 AM
PureTech Health (NASDAQ:PRTC) Shares Gap Up to $25.48PureTech Health (NASDAQ:PRTC) Shares Gap Up to $25.48
marketbeat.com - April 17 at 2:15 PM
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary FibrosisPureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
finance.yahoo.com - April 16 at 7:49 AM
US FDA hands fast track to PureTech head and neck cancer treatmentUS FDA hands fast track to PureTech head and neck cancer treatment
lse.co.uk - April 11 at 8:26 AM
PureTechs LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck CancersPureTech's LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck Cancers
markets.businessinsider.com - April 11 at 8:26 AM
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck CancersPureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
businesswire.com - April 11 at 7:00 AM
PureTech Health (NASDAQ:PRTC) Sees Unusually-High Trading VolumePureTech Health (NASDAQ:PRTC) Sees Unusually-High Trading Volume
marketbeat.com - April 10 at 12:36 PM
PureTech launches Seaport and changes CEOPureTech launches Seaport and changes CEO
thepharmaletter.com - April 9 at 1:47 PM
PureTech launches Seaport, hoping to create Karuna 2.0PureTech launches Seaport, hoping to create Karuna 2.0
biopharmadive.com - April 9 at 1:47 PM
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management TransitionsPureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
businesswire.com - April 9 at 2:00 AM
PureTech Health (NASDAQ:PRTC) Trading Down 5.9%PureTech Health (NASDAQ:PRTC) Trading Down 5.9%
marketbeat.com - April 5 at 1:28 PM
PureTech Health (NASDAQ:PRTC) Sets New 52-Week High at $34.00PureTech Health (NASDAQ:PRTC) Sets New 52-Week High at $34.00
marketbeat.com - April 4 at 5:53 PM
PureTech Health (NASDAQ:PRTC) Shares Gap Down to $30.00PureTech Health (NASDAQ:PRTC) Shares Gap Down to $30.00
marketbeat.com - April 2 at 11:18 AM
PureTech Health (PRTC) is on the Move, Heres Why the Trend Could be SustainablePureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable
zacks.com - April 2 at 9:51 AM
PureTech Health (NASDAQ:PRTC) Shares Gap Up to $28.50PureTech Health (NASDAQ:PRTC) Shares Gap Up to $28.50
marketbeat.com - April 1 at 5:30 PM
PureTech Health (NASDAQ:PRTC) Shares Gap Down to $29.40PureTech Health (NASDAQ:PRTC) Shares Gap Down to $29.40
marketbeat.com - March 27 at 12:23 PM
PureTech rewards shareholders with $100 million tender offerPureTech rewards shareholders with $100 million tender offer
thepharmaletter.com - March 21 at 8:37 AM
Bristol Myers Squibb Completes Acquisition of PureTechs Founded Entity Karuna Therapeutics for $14 BillionBristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
businesswire.com - March 18 at 9:52 AM
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid LeukemiaPureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
finance.yahoo.com - March 13 at 8:41 AM
AKLI Mar 2024 3.000 callAKLI Mar 2024 3.000 call
finance.yahoo.com - February 28 at 1:37 PM
PureTech notes positive results from Shionogis EndeavorRx ADHD trialPureTech notes positive results from Shionogi's EndeavorRx ADHD trial
lse.co.uk - February 27 at 7:53 AM
PureTech to Present at Two Upcoming Investor ConferencesPureTech to Present at Two Upcoming Investor Conferences
finance.yahoo.com - February 27 at 7:53 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bio-Rad Laboratories logo

Bio-Rad Laboratories

NYSE:BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
BELLUS Health logo

BELLUS Health

NASDAQ:BLU
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Entia Biosciences

OTCMKTS:ERGO
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
MorphoSys logo

MorphoSys

NASDAQ:MOR
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
PureTech Health logo

PureTech Health

NASDAQ:PRTC
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.